Table 2.
Nitric oxide release and in vitro anti-proliferative activities of JS-K and its structural analogues
| Compound | Nitric oxide yielda(%) | IC50b (μM) | IC50c (μM) |
|---|---|---|---|
| JS-K | 85 | 0.2–0.5 | 0.3 |
| 1b | 90 | 4.1 | 9.8 |
| 2b | 79 | 1.9 | 1.9 |
| 3 | 88 | 0.4 | 0.7 |
| 4 | 90 | 0.3 | 0.4 |
| 5 | 83 | 1.1 | 1.0 |
| 6 | 86 | 1.2 | 1.1 |
| 7 | 84 | 1.6 | 1.4 |
| 8 | 98 | 1.4 | 1.1 |
| 9 | 74 | 1.9 | 1.9 |
| 10 | 85 | 5.7 | 5.1 |
| 11 | 87 | 0.4 | 0.5 |
| 12 | 93 | 0.2 | 0.3 |
| 13 | 98 | 0.4 | 0.6 |
| 14 | 99 | 0.6 | 0.6 |
| 15 | 90 | 0.5 | 0.4 |
| 16 | 100 | 0.2 | 0.3 |
| 17 | 68 | 10.8 | 9.6 |
a
Determined by measuring NO release from the compound (70–220 μM) in the presence of glutathione (1–3.5 mM) in 0.1 M pH 7.4 phosphate buffer at 37 °C by chemiluminescence analysis. Yield reported assuming 2 mol of NO per mole of compound.
b
Cell viability studies carried out on HL-60 human leukemia cells.
c
50% inhibitory concentration against proliferation of U937 human leukemia cells; same procedure as that for HL-60.